



**INTERNATIONAL CONFERENCE  
IMMUNOTHERAPY AND CANCER: REALITY AND HOPES  
Naples (Italy), 3 July 2015**

**Conference Chairmen: F. de Marinis (Milan, I) - C. Gridelli (Avellino, I)**

**h 9.00 Welcome and Conference end point:  
C. Gridelli (Avellino, I)**

**I SESSION**

**Chairmen: C. Gridelli (Avellino, I) - G. Tortora (Verona, I)**

**h 9.20 Immunotherapy: mechanism of action and targets  
L. Rivoltini (Milan, I)**

**h 9.40 The evolving role of immunotherapy in cancer treatment  
M. Maio (Siena, I)**

**h 10.00 Appropriate response evaluation criteria  
A. Rossi (Avellino, I)**

**h 10.20 Methodology of clinical trials  
F. Perrone (Naples, I)**

**h 10.40 Discussion**

**h 11.10 Coffee break**

**II SESSION**

**Chairmen: F. Cappuzzo (Livorno, I) – F. Grossi (Genoa, I)**

**h 11.30 Lecture: Immunotherapy of melanoma: a successful example  
P. Ascierto (Naples, I)**

**h 11.50 Predictive biomarkers in immunotherapy: pitfall and reality**  
**M. Barberis (Milan, I)**

**h 12.10 Immunotherapy-related toxicity and its management**  
**A. Passaro (Milan, I)**

**h 12.30 Discussion**

**h 13.00 Lunch**

### **III SESSION**

#### **NSCLC**

**Chairmen: L. Crinò (Perugia, Italy) – F. de Marinis (Milan, Italy)**

**h 14.00 Anti PD-1: phase I-II trials**  
**J. Brahmer (Baltimore, US)**

**h 14.20 Anti PD-1: phase III studies**  
**N.A. Rizvi (New York, US)**

**h 14.50 The role of anti PD-L1**  
**B. Besse (Paris, F)**

**h 15.10 Combination of immunotherapy and targeted therapies in biomarkers-driven disease**  
**E. Felip (Barcelona, E)**

**h 15.30 Discussion**

**h 16.00 Advanced NSCLC: building together a treatment algorithm in the check-point inhibitors era**  
**All Faculty Session III members**  
**Facilitators: F. de Marinis – C. Gridelli**

**h 17.00 Closing remarks**  
**F. de Marinis (Milan, I)**